ID | 1197 |
Name of the vaccine | GVXN SD133 |
Microbe | Bacteria |
Disease name | Bacillary Dysentery (Shigellosis) |
Name of bacteria | Shigella genus |
Type of vaccine | Bioconjugate |
Nucleic acid content | DNA |
Age | 18 to 50 years |
Description of the vaccine | Shigella dysenteriae vaccine. |
Name of the manufacturer | GlycoVaxyn AG |
Name of the manufacturing country | Switzerland |
Year of manufacture | 2010 |
Clinical Phase status | Clinical - Phase 1 |
Bacterial strain | Gram-negative bacteria. |
Efficacy | NA |
Vaccine formulation | Suspension for injection |
Dosage | Two doses, gap of 8 weeks. |
Mechanism of action | O1 specific humoral response. |
Route of administration | Intramuscular |
Indications | NA |
Export | NA |
Approval | NA |
Adjuvant | With or without Aluminium hydroxide |
Repurposing | NA |
Side effects of vaccine | NA |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | 26162850 |
Clinical trial number | NCT01069471 |
Reference | NA |
Other name | NA |
Additional Links | NA
|